08.09.2016 • NewsDede WillamsBayerInvestor

Bayer Investor Calls new Monsanto Bid “too Generous”

(c) Zadorozhnyi Viktor/Shutterstock
(c) Zadorozhnyi Viktor/Shutterstock

An unnamed top-30 investor in Bayer has called the German group’s enhanced $127.50 per share revised offer for Monsanto, aimed at securing a deal to buy U.S. rival Monsanto, “far too generous.” The investor told the news agency Reuters that the sweetened bid “would represent a “heavily overpaid” takeover, should it proceed.

The latest comment echoes concerns expressed earlier by top-level Bayer shareholders to the deal that under current terms would be worth more than $65 billion. Both the strategic rationale and the valuation have been questioned.

At the same time, the investor said it was relieved that Bayer did not seem prepared to offer $135-$145 per share, as some analysts estimate the group could have to pay to clinch a deal. In this case, it said, Bayer would need more equity, which require shareholder approval, and this would not be forthcoming.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.